Patent application number | Description | Published |
20090155767 | Methods for a predictive diagnostic test for tamoxifen - A method for determining the likelihood that a therapy involving administration of tamoxifen to a patient afflicted with an estrogen receptor positive breast cancer will provide a therapeutic benefit to the patient which comprises determining the level of expression of epidermal growth factor receptor present within a non-nuclear compartment in cells present in a breast tissue sample from the patient; and comparing the level of expression so obtained to a predetermined level of expression wherein the likelihood the therapy will provide a therapeutic benefit to the patient is greater if the level of expression in step a) is less than the predetermined level of expression. | 06-18-2009 |
20100062452 | METHODS FOR DETERMINING SIGNAL TRANSDUCTION ACTIVITY IN TUMORS - The method of the invention pertains to determining the signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance. | 03-11-2010 |
20110081665 | Methods for making cancer prognoses based on subcellular localization of biomarkers - This invention provides a method of making a prognosis for a patient afflicted with a type of cancer such as colon cancer, based upon quantification of biomarkers such as thymidylate synthase in subcellular compartments. | 04-07-2011 |
20120245051 | OBJECTIVE, QUANTITATIVE METHOD TO PREDICT HISTOLOGICAL SUBTYPE IN NON-SMALL CELL LUNG CANCER - The invention provides a method for determining the histotype of a non-small cell lung cancer tumor which comprises: (a) determining the levels of expression of each of thyroid transcription factor-1, cytokeratin-5, cytokeratin-13 and epidermal growth factor receptor in a sample from the non-small cell lung cancer tumor; (b) calculating a score based on the levels of expression determined in step (a); and (c) comparing the score obtained in step (b) with a predetermined reference score associated with histotypes of non-small cell lung cancer; wherein the tumor is determined to be an adenocarcinoma if the score obtained in (b) is greater than the predetermined reference score and wherein the tumor is determined to be a squamous cell carcinoma if the score obtained in (b) is less than the predetermined reference score. | 09-27-2012 |
20120270239 | MELANOMA PROGNOSTIC MODEL USING TISSUE MICROARRAYS AND GENETIC ALGORITHMS - The invention provides a method for determining the risk that a patient diagnosed with melanoma will develop a recurrence of melanoma comprising: a) determining the level of expression for each marker of a panel of markers, wherein the panel comprises activating transcription factor 2, p21 | 10-25-2012 |
20120329665 | SYSTEMS AND METHODS FOR AUTOMATED ANALYSIS OF CELLS AND TISSUES - Systems and methods for rapidly analyzing cell containing samples, for example to identify morphology or to localize and quantitate biomarkers are disclosed. | 12-27-2012 |
20130143763 | METHODS FOR DETERMINING SIGNAL TRANSDUCTION ACTIVITY IN TUMORS - The method of the invention pertains to determining signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance. | 06-06-2013 |
20140148353 | PROTEIN EXPRESSION-BASED CLASSIFIER FOR PREDICTION OF RECURRENCE IN ADENOCARCINOMA - A method for making a prognosis for a patient afflicted with a type of cancer which comprises (a) determining in a sample of a tumor from the patient a level of expression for at least three biomarkers from the following group: thyroid transcription factor-1 (TTF1), signal transducer and activator of transcription-3 (STAT-3), beta-catenin and cyclin D1; (b) calculating a score based on the levels of expression determined in step (a); (c) correlating the score obtained in step (b) with a series of predetermined reference scores associated with a series of prognoses; so as to thereby make a prognosis for the patient. | 05-29-2014 |
20140170135 | EGFR EXPRESSION IS ASSOCIATED WITH DECREASED BENEFIT FROM TRASTUZUMAB IN THE NCCTG N9831 TRIAL - The subject invention provides a method for treating a patient having a tumor associated with HER2+ breast cancer comprising: measuring in a sample of the patient's tumor a level of expression of epidermal growth factor receptor protein by using an antibody that detects the cytoplasmic domain of epidermal growth factor receptor; and comparing the level of expression of epidermal growth factor receptor protein in the patient's tumor so measured with a reference value; wherein if the level of expression of epidermal growth factor receptor measured is higher than the reference value, treating the patient with a therapy other than trastuzumab. | 06-19-2014 |